Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Up 1,055.5% in January

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 24,900 shares, an increase of 1,055.5% from the January 15th total of 2,155 shares. Currently, 16.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 3,724 shares, the short-interest ratio is currently 6.7 days. Based on an average daily trading volume, of 3,724 shares, the short-interest ratio is currently 6.7 days. Currently, 16.6% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC increased its holdings in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 24,891 shares of the company’s stock after acquiring an additional 1,215 shares during the quarter. Jane Street Group LLC owned approximately 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 as of its most recent filing with the SEC.

Amplify Weight Loss Drug & Treatment ETF Stock Up 0.5%

Shares of Amplify Weight Loss Drug & Treatment ETF stock traded up $0.13 during mid-day trading on Wednesday, hitting $26.17. The stock had a trading volume of 424 shares, compared to its average volume of 4,269. The firm has a 50-day moving average of $25.78 and a two-hundred day moving average of $24.37. Amplify Weight Loss Drug & Treatment ETF has a 12-month low of $18.56 and a 12-month high of $27.28. The firm has a market cap of $3.92 million, a P/E ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Announces Dividend

The company also recently disclosed an annual dividend, which was paid on Wednesday, December 31st. Shareholders of record on Tuesday, December 30th were issued a dividend of $0.4132 per share. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a dividend yield of 162.0%.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.